404 related articles for article (PubMed ID: 37508557)
21. Interactions between gut bacteria and bile in health and disease.
Long SL; Gahan CGM; Joyce SA
Mol Aspects Med; 2017 Aug; 56():54-65. PubMed ID: 28602676
[TBL] [Abstract][Full Text] [Related]
22. Gut Microbiota Modulates Interactions Between Polychlorinated Biphenyls and Bile Acid Homeostasis.
Cheng SL; Li X; Lehmler HJ; Phillips B; Shen D; Cui JY
Toxicol Sci; 2018 Dec; 166(2):269-287. PubMed ID: 30496569
[TBL] [Abstract][Full Text] [Related]
23. Gut microbiota remodeling reverses aging-associated inflammation and dysregulation of systemic bile acid homeostasis in mice sex-specifically.
Ma J; Hong Y; Zheng N; Xie G; Lyu Y; Gu Y; Xi C; Chen L; Wu G; Li Y; Tao X; Zhong J; Huang Z; Wu W; Yuan L; Lin M; Lu X; Zhang W; Jia W; Sheng L; Li H
Gut Microbes; 2020 Sep; 11(5):1450-1474. PubMed ID: 32515683
[TBL] [Abstract][Full Text] [Related]
24. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.
Li Y; Tang R; Leung PSC; Gershwin ME; Ma X
Autoimmun Rev; 2017 Sep; 16(9):885-896. PubMed ID: 28698093
[TBL] [Abstract][Full Text] [Related]
25. Bile acids as regulatory molecules and potential targets in metabolic diseases.
Xie AJ; Mai CT; Zhu YZ; Liu XC; Xie Y
Life Sci; 2021 Dec; 287():120152. PubMed ID: 34793769
[TBL] [Abstract][Full Text] [Related]
26. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex.
Rizzetto L; Fava F; Tuohy KM; Selmi C
J Autoimmun; 2018 Aug; 92():12-34. PubMed ID: 29861127
[TBL] [Abstract][Full Text] [Related]
27. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice.
Hartmann P; Hochrath K; Horvath A; Chen P; Seebauer CT; Llorente C; Wang L; Alnouti Y; Fouts DE; Stärkel P; Loomba R; Coulter S; Liddle C; Yu RT; Ling L; Rossi SJ; DePaoli AM; Downes M; Evans RM; Brenner DA; Schnabl B
Hepatology; 2018 Jun; 67(6):2150-2166. PubMed ID: 29159825
[TBL] [Abstract][Full Text] [Related]
28. Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids.
Gupta B; Rai R; Oertel M; Raeman R
Semin Liver Dis; 2022 May; 42(2):122-137. PubMed ID: 35738255
[TBL] [Abstract][Full Text] [Related]
29. Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids.
Klaassen CD; Cui JY
Drug Metab Dispos; 2015 Oct; 43(10):1505-21. PubMed ID: 26261286
[TBL] [Abstract][Full Text] [Related]
30. Gut microbiota from coronary artery disease patients contributes to vascular dysfunction in mice by regulating bile acid metabolism and immune activation.
Liu H; Tian R; Wang H; Feng S; Li H; Xiao Y; Luan X; Zhang Z; Shi N; Niu H; Zhang S
J Transl Med; 2020 Oct; 18(1):382. PubMed ID: 33036625
[TBL] [Abstract][Full Text] [Related]
31. Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease.
Li L; Liu T; Gu Y; Wang X; Xie R; Sun Y; Wang B; Cao H
Front Immunol; 2022; 13():974305. PubMed ID: 36211363
[TBL] [Abstract][Full Text] [Related]
32. Undernutrition Shapes the Gut Microbiota and Bile Acid Profile in Association with Altered Gut-Liver FXR Signaling in Weaning Pigs.
Lin S; Yang X; Yuan P; Yang J; Wang P; Zhong H; Zhang X; Che L; Feng B; Li J; Zhuo Y; Lin Y; Xu S; Wu D; Burrin DG; Fang Z
J Agric Food Chem; 2019 Apr; 67(13):3691-3701. PubMed ID: 30864445
[TBL] [Abstract][Full Text] [Related]
33. Gut microbiota-related bile acid metabolism-FXR/TGR5 axis impacts the response to anti-α4β7-integrin therapy in humanized mice with colitis.
Han B; Lv X; Liu G; Li S; Fan J; Chen L; Huang Z; Lin G; Xu X; Huang Z; Zhan L; Lv X
Gut Microbes; 2023; 15(1):2232143. PubMed ID: 37431863
[TBL] [Abstract][Full Text] [Related]
34. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
Chen J; Thomsen M; Vitetta L
J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
[TBL] [Abstract][Full Text] [Related]
35. Elevated levels of circulating short-chain fatty acids and bile acids in type 2 diabetes are linked to gut barrier disruption and disordered gut microbiota.
Zhao L; Lou H; Peng Y; Chen S; Fan L; Li X
Diabetes Res Clin Pract; 2020 Nov; 169():108418. PubMed ID: 32891692
[TBL] [Abstract][Full Text] [Related]
36. Bile Acid Modifications at the Microbe-Host Interface: Potential for Nutraceutical and Pharmaceutical Interventions in Host Health.
Joyce SA; Gahan CG
Annu Rev Food Sci Technol; 2016; 7():313-33. PubMed ID: 26772409
[TBL] [Abstract][Full Text] [Related]
37. Focus on the gut-brain axis: Multiple sclerosis, the intestinal barrier and the microbiome.
Camara-Lemarroy CR; Metz LM; Yong VW
World J Gastroenterol; 2018 Oct; 24(37):4217-4223. PubMed ID: 30310254
[TBL] [Abstract][Full Text] [Related]
38. Bile acids and the gut microbiome.
Ridlon JM; Kang DJ; Hylemon PB; Bajaj JS
Curr Opin Gastroenterol; 2014 May; 30(3):332-8. PubMed ID: 24625896
[TBL] [Abstract][Full Text] [Related]
39. Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders.
Fiorucci S; Distrutti E
Trends Mol Med; 2015 Nov; 21(11):702-714. PubMed ID: 26481828
[TBL] [Abstract][Full Text] [Related]
40. Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence?
Pavlidis P; Powell N; Vincent RP; Ehrlich D; Bjarnason I; Hayee B
Aliment Pharmacol Ther; 2015 Oct; 42(7):802-17. PubMed ID: 26223936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
